This study combines phage display with enzymatic proximity labeling to achieve site-specific modification of native antibody Fab fragments, providing a novel substrate design approach for developing highly homogeneous and stable antibody conjugates, particularly suitable for tumor imaging and targeted therapy experiments requiring precise labeling.
Literature Overview
The article titled 'Phage-Selected Clickable Gln-Donor Peptide for Lys-Selective Fab Labeling Using Engineered Microbial Transglutaminase,' published in the journal Antibodies, systematically explores how to achieve efficient and site-selective labeling of a specific lysine residue (Lys65) on Fab fragments by screening highly reactive glutamine (Gln)-donor peptides via phage display and employing engineered microbial transglutaminase (EzMTG-pG). The authors further introduced an azide group, enabling the modified product to be coupled with fluorescent probes via click chemistry, demonstrating the modular potential of this strategy in antibody functionalization.Background Knowledge
Antibody fragments such as Fab have become important platforms for tumor imaging and targeted therapy due to their small molecular size and strong tissue penetration. However, achieving site-specific modification of these fragments remains challenging. Traditional methods rely on genetic encoding or chemical modification, which often suffer from low efficiency or lack of specificity. Current lysine (Lys) residue modifications are limited by their low reactivity on the antibody surface, and most enzymatic modification systems favor Gln295 in the Fc region, making them unsuitable for fragments lacking Fc domains. Therefore, developing site-selective labeling strategies that do not depend on the Fc region and are applicable to native antibodies has become a key bottleneck. This study addresses this by leveraging the proximity effect generated by the EzMTG-pG fusion protein to enhance recognition of low-reactivity Lys residues, while optimizing Gln-donor substrates through phage display to achieve efficient labeling at Lys65 on Fab fragments.
Research Methods and Experiments
The authors utilized an M13 phage-displayed heptapeptide library, using a biotin-labeled, highly reactive Lys peptide (GSMKHKGS) as a capture probe to screen for Gln-donor peptides capable of crosslinking with Lys residues under microbial transglutaminase (MTG) catalysis. After five rounds of progressive screening, multiple Gln-containing peptide sequences were enriched, with FYPLQMR repeatedly appearing, indicating its high reactivity. Based on this, three N-terminal azide-modified peptides were designed: azido-FYPLQMR-NH₂, azido-FYPLQMRG-NH₂, and azido-YPLQMRG-NH₂, for subsequent click chemistry conjugation.
In validation experiments, EzMTG-pG was used to catalyze the reaction between these azidated peptides and Fab fragments derived from trastuzumab. Reverse-phase HPLC analysis revealed that azido-FYPLQMR-NH₂ exhibited the highest reactivity (71.6% modification rate), with modification efficiency increasing to 89% upon increasing substrate concentration. Peptide mapping confirmed the modification site as Lys65 on the heavy chain of the Fab, verifying the site-specificity of the reaction.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides a chemo-enzymatic approach for site-specific modification of antibody fragments without requiring genetic engineering, particularly suitable for developing therapeutic antibodies that must maintain their native structure. Its dual strategy—enhancing Lys reactivity via proximity effect and improving catalytic efficiency through substrate optimization—offers a new paradigm for overcoming the traditionally low efficiency of MTG systems in Lys modification.
In drug development, this method can be used to construct antibody–drug conjugates with uniform drug-to-antibody ratios (DAR), reducing toxicity risks associated with heterogeneity. In clinical monitoring, fluorescently labeled Fab fragments can enable real-time intraoperative imaging, improving tumor margin identification accuracy. Additionally, this strategy can be extended to other proteins or antibody fragments, promoting standardized preparation of functional probes in disease modeling.
Conclusion
This study successfully achieved efficient and site-specific modification of Lys65 on native antibody Fab fragments by integrating phage display with engineered transglutaminase proximity labeling. The developed azidated Gln-donor peptides not only exhibit high reactivity but are also compatible with click chemistry, providing a modular platform for antibody functionalization. This method requires no genetic manipulation and preserves Fab antigen-binding capacity, significantly outperforming traditional random labeling strategies. From a translational perspective, this technology has the potential to become a cornerstone tool for preparing antibody probes in tumor precision therapy and molecular imaging, especially in diagnostic and therapeutic applications requiring high homogeneity and stability. Future work may further optimize substrate solubility and conjugation efficiency to advance practical applications in ADC development and personalized medicine.
